For Healthcare Professionals
Pro feature
By LB Herbert - October 22, 2015
Research and analysis was conducted on migraine on patients’ symptoms, treatment experience and overall quality of life.  Patients came from the Migraine In America 2015 online survey, in which over 4,500 individuals... READ MORE

By Editorial Team - September 30, 2015
OnabotulinumtoxinA is an approved prophylactic treatment for chronic migraine. Given every 12 weeks, onabotulinumtoxinA is thought to reverse peripheral sensitization, thereby indirectly reducing central sensitization.1 Research suggests that abnormally excitable central and... READ MORE

Featured Poll
Featured poll

What percentage of your migraine patients have experienced previous head/neck injury?